Topics

Companies Related to "Regorafenib Nivoluamb Colorectal Cancer" [Most Relevant Company Matches] [Advanced Search Results] RSS

01:40 EST 26th February 2020 | BioPortfolio

Here are the most relevant search results for "Regorafenib Nivoluamb Colorectal Cancer" found in our extensive corporate database of over 50,000 company records.

Showing "Regorafenib Nivoluamb Colorectal Cancer" Companies 1–25 of 2,500+

Extremely Relevant

Colonix Medical Limited

Colonix Medical Limited has pioneered and refined a new system for the early detection / screening of colorectal cancer and other bowel diseases such as IBD. This system can be used for both symptomatic and non symptomatic patients. Colorectal cancer is often referred to as ‘the silent killer’. If detected early, colorectal cancer treatments are effective and after treatment most sufferers ca...


Relevant

Exact Sciences Corp.

Exact Sciences Corp. is a molecular diagnostics company focused on colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the ...

Exact Sciences Corporation

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA technology is included in the colorectal cancer screening guidelines ...


Targeted Diagnostics and Therapeutics

TDT has emerged as a leader in the development of innovative molecular diagnostics and therapeutics that can improve the quality of life of patients with colorectal cancer and gastrointestinal malignancies. Focused on innovative research and cutting edge technology, TDT has developed highly specific tests to detect colorectal cancer cells in lymph nodes from patients who have undergone surgical st...

Colorectal Cancer Coalition

This critical legislation will ensure that even in tight fiscal times, funding for life-saving federal colorectal cancer research programs can be sustained.

Report Card Coalition

Launched in 2004, the Colorectal Cancer Legislation Report Card initiative is supported by a coalition that includes American Cancer Society Cancer Action Network, American College of Gastroenterology, American Gastroenterological Association, American Society of Colon and Rectal Surgeons, American Society for Gastrointestinal Endoscopy, the Cancer Support Community, C3: Colorectal Cancer Coalitio...

Targeted Diagnostics & Therapeutics, Inc

TDT has emerged as a leader in the development of innovative molecular diagnostics and therapeutics that can improve the quality of life of patients with colorectal cancer and gastrointestinal malignancies. Focused on innovative research and cutting edge technology, TDT has developed highly specific tests to detect colorectal cancer cells in lymph nodes from patients who have undergone surgical st...

Biothera Pharmaceuticals, Inc.

Biothera is a privately held biotechnology company developing Imprime PGG, a clinical stage immunotherapy drug that modulates key immune cells to orchestrate a coordinated immune response to cancer that involves both the innate and adaptive immune system. Proof of concept has been established from single-arm and randomized phase 2 studies in non-small cell...

Enterix Inc

Enterix Inc. is a US-based biotechnology company founded in 1997 that manufactures, markets, and distributes a leading-edge product for colorectal cancer screening. The company also uses this product to provide a colorectal cancer screening service. Enterix is addressing a large and rapidly growing market where there is a demonstrated need for an easy-to-use and cost-effective screening tool – a...

Biothera Pharmaceutical Inc.

Biothera is a privately held biotechnology company developing Imprime PGG, a late clinical stage immunotherapeutic drug candidate that modulates key immune cells to recognize and kill cancer. Proof of concept has been established from single-arm and randomized Phase 2 studies in non-small cell lung cancer (NSCLC), colorectal cancer, and chronic lymp...

Genesis Genomics Inc.

Cancer is the leading cause of pre-mature death in Canada, being responsible for almost 1/3 of all potential years of life lost. During their life-time, 2 in 19 women are expected to develop breast cancer, 1 in 18 will develop colorectal cancer, and 1 in 20 will develop lung cancer. Among men, 1 in 9 will develop prostate cancer during their life-time (National Cancer Institute of Canada, 2000).

Clinical Genomics Pty Ltd

Clinical Genomics is dedicated to improving patient outcomes through early detection of colorectal cancer. Clinical Genomics products span the full spectrum of colorectal cancer testing, lnSure® ONE™, a one sample fecal immunochemical test (FIT) for healthy adults to detect lower GI bleeding, and COLVERA®, a proprietary liquid biopsy blood test ...

C3: Colorectal Cancer Coalition

COLORECTAL CANCER ASSOCIATION OF CANADA

Fight Colorectal Cancer

Headquarters Address:

National Coalition for Quality Colorectal Cancer Screening and Care

Austrian Breast & Colorectal Cancer Study Group (ABCSG)

Bandaid Surgery, PC

Laparoscopic colon surgery, also known as band-aid colon surgery, is a revolutionary colorectal surgical technique pioneered and perfected by Dr.David Blumberg, a Board Certified General and Colorectal Surgeon while in the Department of Surgery at the University of Pittsburgh Medical Center. Company Overview: Band-aid colon surgery is a revolutionary colorectal surgical technique pioneered...

Biomoda, Inc.

Biomoda (www.biomoda.com) is a cancer diagnostics company focused on the development of accurate, inexpensive and noninvasive tests for the early detection of cancer. In addition to its first product for lung cancer, diagnostic assays for cervical, breast, colorectal, bladder, and oral cancers are targeted for development. Current research and development ...

CellMax Life

CellMax Life, Inc. is a precision cancer blood-testing company providing comprehensive, personalized multi-biomarker technology platforms for genetic cancer risk assessment, early detection and personalized treatment of cancer. CellMax Life’s products include CellMax-DNA Genetic Cancer Risk Test, CellMax-LBx Liquid Biopsy, and CellMax-CRC Colorectal C...

Biothera, the Immune Health Company

Biothera is a privately held biotechnology company dedicated to improving immune health. The company is developing pharmaceuticals that engage the innate immune system to fight cancer. Its lead cancer drug Imprime PGG is currently in multiple Phase 2 clinical trials for non-small cell lung and in a Phase 3 for colorectal cancer. (www.biothera.com)

Biothera Pharmaceuticals Inc.

Biothera Pharmaceuticals is a privately held biotechnology company developing Imprime PGG, a first-in-class, mid-clinical stage cancer immunotherapy that orchestrates an integrated anti-cancer immune response in combination with checkpoint inhibitors and tumor-targeting and anti-angiogenesis monoclonal antibodies. Imprime PGG has been well-tolerated in tri...

Universal Diagnostics

Universal Diagnostics (UDX) is an innovative biomedicine company focused on early detection of cancer. By combining world-leading expertise in metabolomics with advanced bioinformatics, UDX is developing simple to use, non-invasive tests to detect cancers early. The first test in development is for the detection of colorectal cancer and precancerous adenom...

Biothera

Biothera, a privately held U.S. biotechnology company, is developing Imprime PGG, a late clinical stage biologic that modulates the immune response to cancer. Data from the most recent randomized phase 2 study of Imprime PGG in first line non-squamous non-small cell lung cancer (NSCLC) was featured as a late-breaking abstract in the Immunotherapy of Cancer...

Dynavax Technologies

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative therapeutic products to treat and prevent infectious diseases, allergies, and cancer. Our versatile, proprietary approaches alter specific immune responses by activating a unique receptor called Toll-Like Receptor 9 (TLR9) found on certain immune system cells. To target TLR9, we are using immunostimulat...


More From BioPortfolio on "Regorafenib Nivoluamb Colorectal Cancer"

Quick Search

Corporate Database Quicklinks